



Biotech Daily

Tuesday June 14, 2022

Daily news on ASX-listed biotechnology companies

Actinogen Medical Plans Xanamem For Alzheimer's, Depression Phase II Trials

[ACTINOGEN MEDICAL](#)

Actinogen has detailed its plans for two phase II trials of Xanamem for Alzheimer's disease and major depressive disorder.

Actinogen said that the phase II trials followed its 107 healthy adult phase Ib, 'Xanamia' study of Xanamem for cognition, which met its primary safety, pharmacodynamic and efficacy endpoints (BD: Apr 27, 2022).

The company said that its 300-patient, Alzheimer's disease, phase II trial would be a six-month, dose-ranging, placebo-controlled study of the effects of 5mg and 10mg Xanamem on cognition, with results expected in 2024.

Actinogen said that patients in the Alzheimer's study would include people with early stages of Alzheimer's disease, patients with mild cognitive impairment and patients with mild Alzheimer's disease.

The company said that its 120-patient, major depressive disorder, phase II trial would be a six-week, proof-of-concept, placebo-controlled study of 10mg Xanamem daily or placebo, in addition to anti-depressant therapy, to test the effects on both depression and cognition, with results expected in late 2023 or 2024.

Actinogen said the trial would include patients with persistent major depressive disorder and cognitive difficulties despite a standard course of anti-depressant therapy.

Actinogen chief executive officer Dr Steven Gourlay said the results from the recent Xanamia trial were “exciting and highly confirmatory”.

“We are now initiating two robust phase II trials in patients with Alzheimer’s disease and depression,” Dr Gourlay said.

“Xanamem has the potential to be an effective low-dose daily oral therapy for these and many conditions where it may be used alone or in combination with other treatments,” Dr Gourlay said.

Actinogen fell 0.1 cents or 1.7 percent to 5.9 cents with 2.9 million shares traded.